- Fosun Pharma’s net income for the fiscal year was 2.77 billion yuan, surpassing the estimated 2.72 billion yuan.
- The company’s revenue totaled 41.07 billion yuan, which was slightly below the anticipated 42.24 billion yuan.
- Earnings per share (EPS) stood at 1.04 yuan.
- Analysts’ recommendations for Fosun Pharma include five buy ratings, four hold ratings, and zero sell ratings.
A look at Shanghai Fosun Pharmaceutical (Group) Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a pharmaceutical company that has been given a positive long-term outlook based on various factors. With a solid Value score of 4, the company is considered to have strong fundamentals and growth potential. Its Dividend score of 3 indicates a moderate level of dividend payments to investors, adding to its attractiveness for those seeking income.
Furthermore, Shanghai Fosun Pharmaceutical (Group) has received decent scores in Growth, Resilience, and Momentum, with scores of 3, 3, and 2 respectively. This suggests that the company is positioned for stable growth, has the capability to withstand economic challenges, and is gradually building momentum in the market. Overall, the Smartkarma Smart Scores indicate a promising future for Shanghai Fosun Pharmaceutical (Group) in the pharmaceutical industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
